KR20240013792A - 헤테로시클릭 화합물 및 사용 방법 - Google Patents

헤테로시클릭 화합물 및 사용 방법 Download PDF

Info

Publication number
KR20240013792A
KR20240013792A KR1020237044751A KR20237044751A KR20240013792A KR 20240013792 A KR20240013792 A KR 20240013792A KR 1020237044751 A KR1020237044751 A KR 1020237044751A KR 20237044751 A KR20237044751 A KR 20237044751A KR 20240013792 A KR20240013792 A KR 20240013792A
Authority
KR
South Korea
Prior art keywords
cancer
subject
ras
linked
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044751A
Other languages
English (en)
Korean (ko)
Inventor
아담 마크 레빈슨
에블린 호우앙
히데유키 이가와
킴 루이스 허스트
병찬 김
아바 엘리아스 레플러
마리아 앙헬 팔로메로-바스케스
에릭 테리엔
시안하이 후앙
칼 숀 와츠
스티븐 앨버니지
제임스 알렉산더 고든
앤드루 플라책
Original Assignee
슈뢰딩거, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈뢰딩거, 인크. filed Critical 슈뢰딩거, 인크.
Publication of KR20240013792A publication Critical patent/KR20240013792A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237044751A 2021-05-27 2022-05-26 헤테로시클릭 화합물 및 사용 방법 Pending KR20240013792A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163193831P 2021-05-27 2021-05-27
US63/193,831 2021-05-27
US202163226980P 2021-07-29 2021-07-29
US63/226,980 2021-07-29
PCT/US2022/031133 WO2022251497A1 (en) 2021-05-27 2022-05-26 Heterocyclic compounds and methods of use

Publications (1)

Publication Number Publication Date
KR20240013792A true KR20240013792A (ko) 2024-01-30

Family

ID=84229207

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044751A Pending KR20240013792A (ko) 2021-05-27 2022-05-26 헤테로시클릭 화합물 및 사용 방법

Country Status (5)

Country Link
US (1) US20240279221A1 (https=)
EP (1) EP4346815A4 (https=)
JP (1) JP2024521818A (https=)
KR (1) KR20240013792A (https=)
WO (1) WO2022251497A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334095A (zh) * 2021-12-23 2023-09-01 大陸商北京望實智慧科技有限公司 Ｓｏｓ１抑制劑
EP4463454A1 (en) 2022-01-14 2024-11-20 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
CR20240362A (es) * 2022-02-04 2024-10-03 Schroedinger Inc Compuestos heterocíclicos y métodos de uso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801996A1 (ru) * 2006-04-20 2009-04-28 Глаксо Груп Лимитед 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
ATE459358T1 (de) * 2006-12-20 2010-03-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor- antagonisten
WO2014169843A1 (en) * 2013-04-18 2014-10-23 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
EP3189049B1 (en) * 2014-09-05 2024-03-20 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
RS64167B1 (sr) * 2017-12-21 2023-05-31 Boehringer Ingelheim Int Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori
TW202334095A (zh) * 2021-12-23 2023-09-01 大陸商北京望實智慧科技有限公司 Ｓｏｓ１抑制劑
CN118574830A (zh) * 2022-01-28 2024-08-30 中山优理生物医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用

Also Published As

Publication number Publication date
EP4346815A4 (en) 2025-04-02
US20240279221A1 (en) 2024-08-22
JP2024521818A (ja) 2024-06-04
WO2022251497A1 (en) 2022-12-01
EP4346815A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7728367B2 (ja) がんを処置するために使用され得る尿素誘導体
CN102574852B (zh) Akt抑制剂
JP7797513B2 (ja) がんの処置に有用なピロロ［３，２－ｃ］ピリジン－４－オン誘導体
JP2022507527A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
TW202523326A (zh) 雜環及其用途
KR20240013792A (ko) 헤테로시클릭 화합물 및 사용 방법
TW202227063A (zh) 治療癌症之方法
WO2022094271A1 (en) Methods for treating cancer
TW202340212A (zh) 治療性化合物及其使用方法
KR20220018475A (ko) Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진
AU2023215383A1 (en) Heterocyclic compounds and methods of use
WO2022072645A2 (en) Methods for treating cancer
JP2025535066A (ja) がんを治療するための方法
WO2023173083A1 (en) Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
WO2023245015A2 (en) Phenyl amide compounds and methods of use
CN117715642A (zh) 杂环化合物和使用方法
CN118974038A (zh) 杂环化合物和使用方法
EA050352B1 (ru) Гетероциклические соединения и способы использования
JP2023541047A (ja) がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
WO2025235874A1 (en) Heterocyclics as egfr inhibitors
WO2026015745A1 (en) Macrocyclic ras inhibitors
HK40128998A (zh) 治疗癌症的方法
HK40099028A (zh) 氧氮杂䓬化合物及其在癌症治疗中的用途
TW202300150A (zh) 環狀化合物及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application